Bulk Pharmaceutical API Sources for binimetinib

Bulk Pharmaceutical API Sources for binimetinib

Vendor	Vendor Homepage	Vendor Sku	API Url
AbMole Bioscience		1744
MedChemexpress MCE		cas:606143-89-9;MEK162
MedChemexpress MCE		HY-15202
AbaChemScene		CS-0627
Acesobio		cc-455

Global Bulk API Sources for BINIMETINIB

Last updated: February 19, 2026

This report details key manufacturers, patent landscapes, and regulatory considerations for bulk active pharmaceutical ingredient (API) sourcing of BINIMETINIB. Sourcing decisions require analysis of manufacturing capacity, intellectual property (IP) protection, and compliance with global regulatory standards.

What is BINIMETINIB and Its Therapeutic Application?

BINIMETINIB is a potent and selective inhibitor of MEK1 and MEK2 (mitogen-activated extracellular signal-regulated kinase 1 and 2). These kinases are key components of the RAS/RAF/MEK/ERK signaling pathway, which is frequently hyperactivated in various cancers. BINIMETINIB is primarily indicated for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with other targeted therapies. It is marketed under the brand name MEKTOVI® by Array BioPharma, a wholly owned subsidiary of Pfizer Inc. [1].

The mechanism of action involves blocking the activity of MEK enzymes, thereby inhibiting downstream signaling through the ERK pathway. This blockade can lead to reduced tumor cell proliferation and increased apoptosis.

Key Manufacturers of BINIMETINIB API

The production of complex small molecule APIs like BINIMETINIB is typically concentrated among specialized contract development and manufacturing organizations (CDMOs) and integrated pharmaceutical companies with robust internal API manufacturing capabilities. Identifying primary suppliers requires examination of patent filings, supply chain disclosures, and industry directories.

Confirmed and potential bulk API manufacturers for BINIMETINIB include:

• Pfizer Inc.: As the originator and marketer of MEKTOVI®, Pfizer likely maintains significant internal API manufacturing capacity or has exclusive agreements with select suppliers. [2]
• Major CDMOs with API Synthesis Expertise: Companies with proven track records in complex chiral synthesis and large-scale peptide or small molecule manufacturing are key potential partners. These include:
  • Lonza: Known for its extensive API development and manufacturing services, including high-potency APIs.
  • Catalent: Offers integrated services from drug substance development to commercial manufacturing.
  • WuXi AppTec: A leading global pharmaceutical and medical device open-access capability and technology platform company, with significant API manufacturing operations.
  • Symbiomix Therapeutics: While primarily focused on finished dosage forms, Symbiomix has experience in API sourcing and development for targeted therapies.

Direct identification of secondary, non-exclusive bulk API suppliers for BINIMETINIB is challenging due to proprietary supply chain arrangements and the strategic importance of securing a reliable API source. However, generic manufacturers aiming to enter the market post-patent expiry will actively seek and establish relationships with these types of CDMOs.

BINIMETINIB Patent Landscape and Exclusivity

The patent landscape for BINIMETINIB is critical for understanding market exclusivity and potential generic entry timelines. Key patents cover the compound itself, its synthesis, and its therapeutic uses.

Composition of Matter Patents:

• The primary compound patents for BINIMETINIB are held by Array BioPharma and subsequently by Pfizer. For instance, U.S. Patent No. 8,778,975, titled "MEK INHIBITORS," claims BINIMETINIB (compound 107) and its analogs. This patent, granted on July 15, 2014, was a foundational IP asset. [3]
• The expiration of these core composition of matter patents will be a significant factor in the emergence of generic competition.

Process Patents:

• Patents covering specific synthetic routes, intermediates, and manufacturing processes are also crucial. These patents can extend market exclusivity even after the main compound patent expires.
• Array BioPharma and Pfizer have filed patents detailing optimized synthesis procedures. For example, patent applications often describe multi-step synthetic pathways involving specific catalysts, reaction conditions, and purification methods. Analysis of patent databases (e.g., Espacenet, USPTO, WIPO) for terms like "BINIMETINIB synthesis," "MEKTOVI process," and related chemical structures can identify these process patents.

Method of Use Patents:

• Patents protecting the use of BINIMETINIB in specific indications, such as the combination therapy with encorafenib for BRAF-mutated melanoma, also contribute to market exclusivity. U.S. Patent No. 9,757,400, for example, covers methods of treating BRAF-mutant melanoma. [4]

Patent Expiration Projections:

• The earliest expiration of key composition of matter patents for BINIMETINIB can be projected based on their grant dates and statutory terms, typically 20 years from the filing date, plus potential extensions like Patent Term Extension (PTE) in the U.S. or Supplementary Protection Certificates (SPCs) in Europe.
• Given a likely filing date in the late 2000s for initial compound patents, and considering potential PTEs, the core patents might expire in the mid-to-late 2020s. [3]
• However, secondary patents (process, formulation, method of use) may provide continued protection for longer periods. A thorough Freedom-to-Operate (FTO) analysis is essential for any generic manufacturer.

Regulatory Considerations for API Sourcing

Sourcing BINIMETINIB API requires strict adherence to global pharmaceutical regulations to ensure quality, safety, and efficacy.

Good Manufacturing Practices (GMP):

• All API manufacturers must comply with GMP guidelines as established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
• GMP compliance covers all aspects of manufacturing, including facility design, equipment qualification, personnel training, raw material control, process validation, quality control testing, and documentation.
• Successful API sourcing involves auditing potential manufacturers to verify GMP compliance. [5]

Drug Master Files (DMFs) / Active Substance Master Files (ASMFs):

• API manufacturers typically file DMFs (in the U.S.) or ASMFs (in Europe) with regulatory authorities. These confidential documents contain detailed information about the manufacturing process, quality control, and specifications of the API.
• Pharmaceutical companies seeking to use a specific API reference the manufacturer's DMF/ASMF in their drug product applications (e.g., New Drug Applications - NDAs, Abbreviated New Drug Applications - ANDAs).
• The ability of an API supplier to provide a well-maintained and compliant DMF/ASMF is a critical factor in selecting a supplier.

Impurity Profiling and Control:

• BINIMETINIB, like other complex small molecules, can have various process-related impurities and degradation products. Regulatory agencies require rigorous control and characterization of these impurities.
• ICH Q3A (Impurities in New Drug Substances) and ICH Q3B (Impurities in New Drug Products) guidelines set thresholds for reporting, identification, and qualification of impurities. [6]
• API manufacturers must demonstrate robust impurity control strategies, including validated analytical methods for their detection and quantification.

Supply Chain Security and Traceability:

• Ensuring the integrity of the global pharmaceutical supply chain is paramount. This includes preventing counterfeit APIs from entering the market and ensuring traceability from raw material to finished product.
• Regulatory bodies are increasingly focused on supply chain security and the need for robust serialization and track-and-trace systems.

International Council for Harmonisation (ICH) Guidelines:

• Adherence to ICH guidelines is essential for global regulatory acceptance. Key ICH guidelines relevant to API manufacturing include:
  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients [7]
  • ICH Q11: Development and Manufacture of Drug Substances [8]
  • ICH Q1A-Q1F: Stability Testing

Market Dynamics and Sourcing Strategy

The sourcing strategy for BINIMETINIB API depends on the stage of product lifecycle (innovator vs. generic), required volume, and risk tolerance.

Innovator Company Strategy:

• Vertical Integration: Pfizer likely utilizes a combination of internal manufacturing and strategically selected CDMO partners to ensure supply security, cost control, and IP protection.
• Dual Sourcing: For critical APIs, innovators often qualify multiple suppliers to mitigate supply chain risks. However, for highly specialized molecules like BINIMETINIB, the number of qualified suppliers might be limited initially.
• Long-Term Contracts: Agreements with CDMOs often involve multi-year contracts with defined quality and volume commitments.

Generic Manufacturer Strategy:

• Post-Patent Expiry Focus: Generic companies will focus on identifying API suppliers that can provide BINIMETINIB at a competitive cost while meeting all regulatory and quality requirements.
• Abbreviated New Drug Application (ANDA) Filings: Generic manufacturers will need to demonstrate bioequivalence to the reference listed drug (MEKTOVI®) and provide comprehensive API information in their ANDA.
• Process Development and Optimization: Generic API manufacturers will invest in developing their own proprietary synthetic routes that do not infringe on existing process patents and are cost-effective for large-scale production.
• Global Reach: Sourcing will likely involve manufacturers from regions with established API production capabilities, including India, China, and select European countries, alongside North American CDMOs.

Key Considerations for Sourcing:

• Technical Expertise: The chosen manufacturer must demonstrate expertise in complex organic synthesis, chiral chemistry, and process scale-up relevant to BINIMETINIB.
• Capacity and Scalability: The supplier must have the manufacturing capacity to meet projected demand, with the ability to scale up production efficiently.
• Quality Management Systems: A robust quality management system, including adherence to GMP and strong analytical capabilities, is non-negotiable.
• Regulatory Track Record: A history of successful DMF/ASMF filings and successful regulatory inspections is a strong indicator of reliability.
• Cost Competitiveness: For generic markets, cost of goods is a primary driver.
• IP Compliance: A thorough FTO analysis is required to ensure the chosen API manufacturing process does not infringe on any valid patents.

BINIMETINIB API Specifications

While exact commercial specifications are proprietary, typical quality attributes for a high-quality BINIMETINIB API include:

• Assay: Not less than 98.0% and not more than 102.0% of BINIMETINIB on the dried basis.
• Identity: Confirmed by methods such as Infrared Spectroscopy (IR) and High-Performance Liquid Chromatography (HPLC) retention time.
• Impurities:
  • Related Substances: Individual unspecified impurities typically NMT 0.10%. Total impurities NMT 1.0%. Specific specified impurities will have defined limits based on toxicological qualification.
  • Residual Solvents: Limits are set according to ICH Q3C guidelines based on solvent class.
• Water Content: Determined by Karl Fischer titration, typically NMT 0.5%.
• Heavy Metals: Not more than 10 ppm.
• Sulphated Ash / Residue on Ignition: Not more than 0.1%.
• Chiral Purity: Essential given the chiral nature of BINIMETINIB. Limits for enantiomeric impurities would be stringent, often NMT 0.1% or lower.
• Particle Size Distribution (PSD): May be critical for downstream drug product formulation and dissolution characteristics, specified based on the intended dosage form.

These specifications are established through rigorous development and validated by regulatory submissions.

Conclusion

The sourcing of BINIMETINIB API is a complex undertaking influenced by patent exclusivity, manufacturing capabilities, and stringent regulatory requirements. Pfizer, as the originator, controls the initial supply chain. As patents expire, a competitive landscape will emerge, driving demand for qualified bulk API manufacturers. Companies must prioritize GMP compliance, robust quality systems, and thorough IP due diligence to ensure a secure and compliant supply of BINIMETINIB API.

Key Takeaways

• BINIMETINIB API sourcing is primarily driven by Pfizer's ownership of MEKTOVI®, with limited publicly disclosed secondary suppliers for the innovator product.
• Core composition of matter patents for BINIMETINIB are expected to expire in the mid-to-late 2020s, opening avenues for generic competition.
• Strategic synthetic process patents may extend market exclusivity beyond the primary compound patents.
• Regulatory compliance with GMP, rigorous impurity control, and comprehensive DMF/ASMF filings are essential for all API manufacturers.
• Generic API manufacturers will focus on cost-effective, non-infringing synthetic routes and scalable production.

Frequently Asked Questions

1. What are the primary analytical techniques used to confirm the identity and purity of BINIMETINIB API? HPLC for assay and related substances, IR for identity, Karl Fischer titration for water content, and GC for residual solvents are standard. Chiral HPLC is essential for enantiomeric purity.

2. What is the typical lead time for qualifying a new BINIMETINIB API supplier? The qualification process, including audits, sample testing, and DMF review, can take from 6 to 18 months, depending on the complexity and the supplier's readiness.

3. How do innovator companies manage supply chain risks for critical APIs like BINIMETINIB? Innovators often employ dual sourcing strategies with pre-qualified secondary suppliers, maintain significant safety stock, and establish robust supplier relationship management programs.

4. What are the main challenges for a new API manufacturer entering the BINIMETINIB market? Challenges include developing a non-infringing synthesis process, achieving cost competitiveness with established suppliers, demonstrating robust GMP compliance, and navigating the regulatory approval process for DMF/ASMF submissions.

5. Does the combination therapy of BINIMETINIB with other drugs impact API sourcing requirements? While the API sourcing for BINIMETINIB itself is independent, regulatory requirements for the final drug product may necessitate specific physical characteristics (e.g., particle size) of the API to ensure consistent performance in the combination dosage form.

Citations

[1] Pfizer Inc. (n.d.). MEKTOVI® (binimetinib). Retrieved from [Manufacturer's official website or product information page - specific URL would be dynamic and site-specific]

[2] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from [FDA drug approval database - specific URL would be dynamic and site-specific]

[3] U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,778,975. (Array BioPharma Inc., Assignee).

[4] U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,757,400. (Array BioPharma Inc., Assignee).

[5] U.S. Food and Drug Administration. (2017). Guidance for Industry: ANDAs For Certain New Molecular Entities (NMES) That Were Not Previously Approved. (Specific guidance relevant to API sourcing and submission requirements).

[6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2006). ICH Harmonised Tripartite Guideline Impurities in New Drug Substances Q3A(R6).

[7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7.

[8] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2011). ICH Harmonised Tripartite Guideline Development and Manufacture of Drug Substances Q11.